Pacer Advisors Inc. reduced its holdings in Progyny, Inc. (NASDAQ: PGNY) by 28.5% in the undefined quarter, according to the company in its most recent filing with the SEC. The firm owned 385,079 shares of the company's stock after selling 153,120 shares during the quarter. Pacer Advisors Inc. owned approximately 0.45% of Progyny

Progyny (NASDAQ: PGNY - Get Free Report) and Zicix (OTCMKTS:ZICXD - Get Free Report) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, institutional ownership, profitability, valuation and earnings. Volatility and Risk Progyny has a beta of 0.97, suggesting

Progyny (PGNY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Progyny (PGNY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Edgestream Partners L.P. increased its holdings in shares of Progyny, Inc. (NASDAQ: PGNY) by 99.5% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 162,397 shares of the company's stock after acquiring an additional 81,004 shares during the quarter. Edgestream Partners L.P. owned

CEO Anevski now owns $17 million worth of Progyny. Progyny's stock popped roughly 8% the day of the announcement.

Progyny (PGNY) possesses solid growth attributes, which could help it handily outperform the market.

NEW YORK, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in family building solutions, today announced new men's health research exploring experiences and views on fertility. The findings shed light on how men in the U.S. view their role in the fertility journey and the barriers that prevent many from getting the care they need for successful conception.

Progyny (PGNY) surges after strong Q3 earnings, robust client growth, and a $200M share buyback, signaling renewed momentum and market confidence. PGNY overcame Amazon's departure by adding new clients, achieving near 100% renewal rates, and accelerating revenue growth across both business segments. Analyst upgrades, insider buying, and secular tailwinds—like rising infertility and delayed childbirth—support a bullish outlook and reinforce the company's competitive moat.

Progyny is a leader in fertility benefits, offering employers comprehensive, outcomes-based solutions that improve treatment success and manage costs. Its focused model has driven strong demand and set it apart in a niche that's expanding quickly within the healthcare sector.